Health economics of chronic infectious diseases: The example of hepatitis C;Gesundheitsökonomische Aspekte chronischer Infektionskrankheiten am Beispiel der chronischen Hepatitis C

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 49, Issue 1, 2006, Pages 57-63

  Wasem, Juergen ^a   Sroczynski, G ^b,c   Aidelsburger, P ^a,d   Buchberger, B ^a   Hessel, F ^a   Conrads Frank, A ^b   Peters Blochinger A ^c   Kurth, B M ^e   Wong, J B ^f   Rossol, S ^g   Siebert, U ^b,c,h  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d CAREM GmbH ^*  (Germany)

^e ROBERT KOCH INSTITUTE   (Germany)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Gesundheits und Pflegezentrum Russelsheim   (Germany)

^h Institut für angewandte Systemforschung und entwicklung   (Germany)

Author keywords

Comorbidity; Cost effectiveness; GEHMO; HCV

Indexed keywords

ARTICLE; CHRONIC DISEASE; COST BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT SYSTEM; ECONOMICS; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HEPATITIS C; HUMAN; INFECTION; METHODOLOGY; RESEARCH; STATISTICAL MODEL; STATISTICS;

CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; ECONOMICS, MEDICAL; GERMANY; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INFECTION; MODELS, ECONOMIC; RESEARCH;

EID: 33644924103     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-005-1190-7     Document Type: Article

References (38)

1. WHO (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatitis 6:35-47
2. Schreier E, Höhne M (2001) Hepatitis C - Epidemiologie und Prävention. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44:554-561
3. Wong JB et al. (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90(10):1562-1569
4. Krahn MD, John-Baptiste A, Yi Q et al. (2005) Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 23 1549-1558
5. Siebert U (2003) When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial]. Eur J Health Economics 4(3):143-150
6. Bennett W, Inoue Y, Beck J et al. (1997). Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Internal Med 127(10):855-865
7. Wong J, Poynard T, Ling M et al. (2000) Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 95(6):1524-1530
8. Siebert U, Sroczynski G, Rossol S et al. (2003) Cost-effectiveness of peginterferon a-2b plus ribavirin versus interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52:425-432
9. Siebert U, Sroczynski G, on behalf of the German Hepatitis C Model (GEHMO) Group and the HTA Expert Panel on Hepatitis C (2003) Antivirale Therapie bei Patienten mit chronischer Hepatitis C in Deutschland. Medizinische und ökonomische Evaluation der initialen Kombinationstherapie mit Interferon/Peginterferon und Ribavirin. Schriftenreihe HTA des Deutschen Instituts für Medizinische Dokumentation und Information im Auftrag des Deutschen Bundesministeriums für Gesundheit und Soziale Sicherung. Health Technology Assessment, Vol. 8. DIMDI, Köln
10. Wong JB, Silvestere D, Siebert U (2004) Cost-effectiveness of treatment of Hepatitis C in injecting drug users. In: Jager JLW, Kretzschmar M, Postma M, Wiessing L (eds) Hepatitis C and injecting drug use: Impact, costs and policy options, Vol. 7. European Communities, Luxembourg, pp 219-244
11. Siebert U, Sroczynski G, Wasem J et al. (2005) Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ. DOI: 10.1007/s10198-005-0280-7
12. Siebert U, Wasem J, Rossol S et al. (2005) Antiviral treatment initiation costs in chronic hepatitis C. Gut 54(1):172-173
13. Knodell RG, Ishak KG, Black WG et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1(5):431-435
14. Desmet VJ, Gerber M, Hoofnagle JH et al. (1994) Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19(6):1513-1520
15. Siebert U, Ravens-Sieberer U et al. (2003) Performance of different utility assessment methods in chronic hepatitis C patients. In: Kind P, Macran S (eds) Proceedings of the 19th Plenary Meeting of the EuroQol Group. 13th-14th September 2002 Discussion Papers. Centre for Health Economics, University of York, York, pp 175-184
16. Robert Koch-Institut (2002) Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis B und C bis zum Jahr 2001. Epidemiol Bull 44:360-376
17. Robert Koch-Institut (2003) Infektionsepidemiologisches Jahrbuch Meldepflichtiger Krankheiten für 2002. (http://rki.de)
18. Falck-Ytter Y, Kale H, Mullen K et al. (2002) Surprisingly small effect of antiviral treatment in patients with Hepatitis C. Ann Internal Med 136:228-292
19. Kjaergard L, Krogsgaard K, Gluud C (2001) Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials. BMJ 323(7322):1151-1155
20. Kjaergard L, Krogsgaard K, Gluud C (2002) Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C (Cochrane Review). Cochrane Database of Systematic Reviews (1)
21. Manns M, McHutchison J, Gordon S et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358(9286):958-965
22. Fried M, Shiffman M, Reddy K et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982
23. Torrance GW, Feeny DH, Furlong WJ et al. (1996) Multiattribute utility function for a comprehensive health status classification system. Medical Care 34:701-722
24. Von der Schulenburg JM, Claes C, Greiner W, Uber A (1998) Die deutsche Version des EuroQol-Fragebogens. Z Gesundheitswissenschaften 6:3-20
25. Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based single measure for health from the SF-36. Journal of Health economics
26. Greiner W (1999) Ökonomische Evaluation von Gesundheitsleistungen: Fragestellungen, Methoden und Grenzen dargestellt am Beispiel der Transplantationsmedizin. Nomos-Verlags-Gesellschaft, Baden-Baden
27. Drummond MF, O'Brien B, Stoddart GL, WT G (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, New York
28. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
29. AG Reha-ökonomie im Förderschwerpunkt Rehabilitationswissenschaften (1999) In: Hessel F, Kohlmann T, Krauth C et al. (Hrsg) Gesundheitsökonomische Evaluation in der Rehabilitation. Teil I: Prinzipien und Empfehlungen für die Leistungserfassung. DRV-Schriften, Band 16: Förderschwerpunkt "Rehabilitationswissenschaften". Empfehlungen der Arbeitsgruppen "Generische Methoden", "Routinedaten und Reha-ökonomie". VDR, Frankfurt, S 106-193
30. Weinstein MC (1999) High-priced technology can be good value for money. Ann Internal Med 130(10):857-858
31. Wong JB, Sonnenberg FA, Salem DN, Pauker SG (1990) Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data availible in 1989. Ann Internal Med 113(11):852-881
32. Shepherd J, Brodin H, Cave C, et al. (2004) Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 8 (39), 1-125
33. Shepherd J, Brodin H, Cave C et al. (2005) Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Int J Technol Assess Health Care 21(2):47-54
34. Wagstaff A (1991) QALYs and the equity-efficiency trade-off. J Health Econ 10:21-41
35. Johannesson M, Gerdtham U (1996) A note on the estimation of the equity-efficiency trade-off for QALYs. J Health Econ 15(3):359-368
36. Lindholm L, Rosen M et al. (1996) An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy. Health Policy 35(3):205-216
37. Lindholm L, Rosen M et al. (1998) How many lives is equity worth? A proposal for equity adjusted years of life saved. J Epidemiol Community Health 52(12):808-811
38. Sassi F, Archard L, Le Grand J (2001) Equity and the economic evaluation of healthcare. Health Technol Assess 5(3)